Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα AgonistMichael R. McKeown, Ravindra Majeti, Emily Lee et al.|Cancer Discovery|2017Cited by 139
Abstract 1511: AML patient clustering by super-enhancers reveals an RARA associated transcription factor signaling partnerMichael R. McKeown, Christian Fritz, Matthew L. Eaton et al.|Cancer Research|2017Cited by 0